We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
South Africa's government has awarded three-year contracts to seven pharmaceutical
companies to produce antiretroviral drugs for distribution in public health
facilities across the country, Reuters reports.
Officials of the Philippines-India Business Council called on the government
Monday to allow importation of medicines outside the government's "Botika
ng Bayan" program, which could lower prices of essential drugs by as much
as 75 percent.
Neuren Pharmaceuticals and Metabolic Pharmaceuticals have agreed to collaborate
to co-develop a class of nerve repair compounds for the treatment of degenerative
conditions such as peripheral neuropathy, motor neuron disease and repairing
the brain or nerves after injuries.
Evotec OAI AG, the Hamburg-based drug discovery and development company, has
announced the acquisition of the outstanding 78 percent of Evotec Neurosciences
not already owned by Evotec.
Philippine imports of essential and life-saving drugs
from India are expected to rise by a significant 25 percent to US$22.5 million
this year from US$18 million in 2004.
Israel's drug manufacturing sector continues to target export
markets in view of the relatively small and volatile local sector, where sales
are becoming increasingly dominated by imports.
The 2004 data for Brazil's retail drug sales indicate a 10.3% year-on-year
rise to 1.65bn units, and a 17.67% growth in value terms to BRL19.8mn (US$620.14mn).
Hungary's status as one of the most advanced pharmaceutical markets
in Eastern Europe, with per capita spending at US$152 in 2003 and a strong manufacturing
sector, continues to encourage multinationals to build their local presence.
The participation of foreign companies in the Chinese generics sector
has grown notably in recent years, as product lines are often more sophisticated
than the vast majority of local "generic" production, mainly limited
to basic treatments such as anti-infectives.
Peter Stadler, the managing director of German bioscience firm Artemis Pharmaceuticals,
is lobbying his government to set up a venture similar to Scotland's flagship
Intermediary Technology Institutes (ITI) initiative.